v3.26.1
Stockholders' equity
 3 Months Ended
Jun. 30, 2026
Stockholders’ equity [Abstract]  
Stockholders' equity
6. Stockholders’ equity
 
Preferred Stock
 
The Company is authorized to issue up to 10,000,000 shares of preferred stock, par value $0.0001 per share. No shares of the Company’s preferred stock are issued or outstanding.
 
Common Stock
 
In connection with the consummation of the Domestication, on October 7, 2024, the Company adopted a Certificate of Incorporation (as amended, the “Charter”) and Bylaws (as amended, the “Bylaws”). The rights of holders of the Company’s Common Stock are governed by the Charter, the Bylaws, and the General Corporation Law of the State of Delaware. The Company is authorized to issue up to 100,000,000 shares of Common Stock, par value $0.0001 per share.
The Company’s February 2025 pre-funded warrants and common warrants are presented under additional paid-in capital in the equity section of the unaudited condensed consolidated balance sheet as of June 30, 2026.
 
During the three months ended June 30, 2026, 250,000 of the February 2025 pre-funded warrants were exercised for 250,000 shares of Common Stock.
 
The following table summarizes the Company’s outstanding warrants as of June 30, 2026, all of which are exercisable for shares of Common Stock:
 
                
June 30, 2026  
    No. of
warrants 		    Exercise
Price ($) 		    Expiration
Date 		 
Equity classified warrants
              
Pre-funded warrants issued in connection with September 2023 private placement
  338,252    0.0001     No expiration  
Common warrants issued in connection with February 2025 private placement
  4,418,292    3.395    (1) 
Pre-funded warrants issued in connection with February 2025 private placement
  657,708    0.0001     No expiration  
 
1.
The February 2025 common warrants will expire on the earlier of: (i) the 60th day after the date the FDA approves the NDA for GTx-104 or (ii) September 25, 2028.